DNA RNA and Cells

4 August 2014

Final Patient Treated In Neuralstem Phase II ALS Stem Cell Trial

2 August 2014

IntelliCell BioSciences Files Pre-IND With FDA for Osteoarthritis Lead by Dr. James Andrews

2 August 2014

Isis Pharmaceuticals Initiates Phase 3 Study of ISIS-SMN Rx in Infants with Spinal Muscular Atrophy

31 July 2014

NOXXON Initiates Phase IIa Study of Anti-Hepcidin Spiegelmer® Lexaptepid Pegol (NOX-H94) in Dialysis Patients with EPO-hyporesponsive Anemia

29 July 2014

Quark Pharmaceuticals Reports Favorable Results From Phase II Clinical Trial Evaluating Investigational siRNA QPI-1002

29 July 2014

ATL1103 Acromegaly Phase II Trial Dosing Completed

28 July 2014

Stemline Therapeutics Announces Opening of SL-401 Corporate IND and Start of Clinical Trials in BPDCN and AML

26 July 2014

biOasis Releases Quantitative Results: siRNA-Transcendpep Reduces Target Gene Expression in the Brain

22 July 2014

Tekmira Provides Update on TKM-Ebola Phase I Clinical Hold

17 July 2014

Isis Pharmaceuticals Initiates Phase 2 Study of ISIS-APO(a) Rx in Patients with High Lp(a)

17 July 2014

Seres Health Completes Enrollment in a Clinical Study for SER-109 in Recurrent Clostridium difficile Infection and Announces Positive Preliminary Data

10 July 2014

Sarepta Therapeutics Reports Long-Term Outcomes Through 144 Weeks from Phase IIb Study of Eteplirsen in Duchenne Muscular Dystrophy

10 July 2014

Regado Biosciences Announces Clinical Hold of REGULATE-PCI Trial Following Voluntary Halt of Trial by Regado

9 July 2014

Vital Therapies Reports on Clinical Trial Progress and EU Regulatory Advice

9 July 2014

CardioCell Begins Phase IIa Clinical Trial Using itMSC Therapy to Treat Chronic Heart Failure (HF) Due to Non-Ischemic Cardiomyopathy

8 July 2014

Oncolytics Biotech® Inc. Announces Completion of Patient Enrollment in U.S. Randomized Phase II Pancreatic Cancer Study

7 July 2014

Novartis personalized cell therapy CTL019 receives FDA Breakthrough Therapy designation

3 July 2014

Tekmira Receives Notice of Clinical Hold for TKM-Ebola Phase I Clinical Trial

2 July 2014

Jazz Pharmaceuticals Announces Agreement To Acquire Rights To Defibrotide In The Americas From Sigma-Tau Pharmaceuticals, Inc.

2 July 2014

Isis Pharmaceuticals Earns $1 Million From GSK for Advancing Hepatitis B Virus Program

1 July 2014

Quark Announces Completion of Phase II Trial Evaluating QPI-1002 for Prevention of Delayed Graft Function in Kidney Transplant Patients

1 July 2014

OncoGenex Announces Cedar™ Clinical Trial Evaluating Apatorsen in Combination with Chemotherapy in Advanced Squamous Cell Lung Cancer is Now Open for Enrollment

30 June 2014

Researchers Demonstrate Promise of Dicerna Investigational Therapy in Preclinical Model of Primary Hyperoxaluria Type 1 (PH1)

25 June 2014

Quark Announces First Patient Dosed in a Phase IIa Trial Evaluating QPI-1007 for Neuroprotection in Patients With Acute Primary Angle Closure Glaucoma

25 June 2014

Bone Therapeutics Starts Patient Treatment in First Ever Clinical Trial with Allogeneic Bone Cell Therapy Produc

24 June 2014

Cardium Announces Positive Interim Phase 3 Clinical Data Showing Significant Efficacy of Generx® Angiogenic Gene Therapy for Myocardial Ischemia Due to Coronary Artery Disease at the 2014 BIO International Convention

24 June 2014

Isis Pharmaceuticals Earns $1 Million From GSK for Advancing ISIS-TTR

23 June 2014

Inovio Pharmaceuticals Initiates Cervical Cancer Clinical Trial

23 June 2014

Regado Biosciences’ REG2 Demonstrates Dose and Concentration-Dependent Suppression of Thrombin Generation

23 June 2014

LCT Parkinson’s trial resumes patient recruitment

News Channels

Newsletter

La Merie Biologics

La Merie Publishing releases a weekly newsletter with a focus on biopharmaceutical research and development.

Newsletter La Merie Biologics

Newsletter

New Product Alert

La Merie Publishing offers an e-mail notification service about the release of new products of La Merie Publishing. This New Product Release Alert also informs about the release of FREE reports produced by La Merie Publishing.

Newsletter new product alert

Featured reports

Blockbuster Biologics 2019: Sales of Recombinant Therapeutic Antibodies & Proteins

Fibroblast Activation Protein (FAP) Targeted Therapy & Companion Diagnostic Pipeline Review

5T4-Targeted Immunotherapy Candidates Pipeline Review

GPC3-Targeted Immunotherapy Pipeline Review

2020 Sales of Recombinant Therapeutic Antibodies, Proteins, Biosimilars & Other Biologics

Masked Antibodies & Cytokines As Prodrugs: a landscape analysis of stakeholders, technologies, pipelines, business and financing from an industry perspective

Blockbuster Biologics 2017: Sales of Recombinant Therapeutic Antibodies & Proteins

c-Met-Targeted Antibody Therapy Pipeline Review

IGF-1R- and IGF-1 Targeted Immunotherapy Pipeline Review

Ustekinumab (Stelara) Biosimilars Pipeline Review